[Effects of delayed-action tetracosactide on chronic pain].
Beta 1-24 corticotrophin was the object of an open trial in the "acute" treatment of chronic pain in 22 patients. The analgesic effect of the drug was assessed before and after two weeks of treatment by means of 3 subjective tests: visual analogue scale, numeric scale and Mac Gill pain questionnaire. The results were statistically significant (P less than 0.01). They confirmed that slow-release tetracosactide exerts a beneficial effect on the sensory-discriminative and affective-emotional components of pain. The drug may be prescribed for short periods (1 to 2 weeks) to patients with chronic pain refractory to the usual treatments. Its analgesic effect is immediate and enables a conventional treatment to be instituted.
Serrie
A
A
Département d'Anesthésie-Réanimation, Hôpital Lariboisière, Paris.
Cunin
G
G
Ragueneau
J L
JL
Thurel
C
C
D002908:Chronic Disease; D003366:Cosyntropin / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004341:Drug Evaluation; D006801:Humans; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy*; D010147:Pain Measurement
D003692:Delayed-Action Preparations; D003366:Cosyntropin
Effets du tétracosactide retard sur les douleurs chroniques.